MARK2 and cancer: HTATIP2/TIP30 displays a serine-threonine kinase activity that can phosphorylate the carboxyl terminal domain of RNA polymerase II in a TAT-dependent manner [12], suggesting that HTATIP2/TIP30 is a potential target for human cancer treatment.